Literature DB >> 23494875

The role of the CXCR4 cell surface chemokine receptor in glioma biology.

Moneeb Ehtesham1, Elliot Min, Neil M Issar, Rebecca A Kasl, Imad S Khan, Reid C Thompson.   

Abstract

CXCR4, a cell surface chemokine receptor, mediates cellular dissemination, invasion, and proliferation in a wide range of cancers including gliomas. It is over-expressed in glioma progenitor cells, and its protein ligand, CXCL12, has been shown to mediate a specific proliferative response in these cells thereby implicating a role for CXCR4 in glioma initiation and renewal. Given the failure of currently employed therapies to meaningfully impact prognosis in patients with high-grade gliomas, the CXCR4-CXCL12 axis represents a novel biologically relevant mechanism that could be specifically targeted for therapy. From this perspective, this review summarizes the biological effects of CXCR4 activity and its implications for glioma pathogenesis. Ultimately, the development of effective treatment approaches for malignant glioma must be based on a rational mechanistic understanding of tumor cell biology. As such, this article presents such a framework with regard to the CXCR4 pathway in glioma thereby supporting the further investigation of CXCR4 as a therapeutic target in patients with this disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23494875     DOI: 10.1007/s11060-013-1108-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  64 in total

1.  Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma.

Authors:  S A Rempel; S Dudas; S Ge; J A Gutiérrez
Journal:  Clin Cancer Res       Date:  2000-01       Impact factor: 12.531

2.  Stromal-derived factor-1 (CXCL12) regulates laminar position of Cajal-Retzius cells in normal and dysplastic brains.

Authors:  Mercedes F Paredes; Guangnan Li; Omri Berger; Scott C Baraban; Samuel J Pleasure
Journal:  J Neurosci       Date:  2006-09-13       Impact factor: 6.167

3.  Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice.

Authors:  Q Ma; D Jones; P R Borghesani; R A Segal; T Nagasawa; T Kishimoto; R T Bronson; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

4.  Abnormal development of the hippocampal dentate gyrus in mice lacking the CXCR4 chemokine receptor.

Authors:  Meiling Lu; Elizabeth A Grove; Richard J Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

5.  Butein downregulates chemokine receptor CXCR4 expression and function through suppression of NF-κB activation in breast and pancreatic tumor cells.

Authors:  Angeline Wei Ling Chua; Hui Sin Hay; Peramaiyan Rajendran; Muthu K Shanmugam; Feng Li; Pradeep Bist; Evelyn S C Koay; Lina H K Lim; Alan Prem Kumar; Gautam Sethi
Journal:  Biochem Pharmacol       Date:  2010-08-10       Impact factor: 5.858

Review 6.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

7.  Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion.

Authors:  David Zagzag; Yevgeniy Lukyanov; Li Lan; M Aktar Ali; Mine Esencay; Olga Mendez; Herman Yee; Evelyn B Voura; Elizabeth W Newcomb
Journal:  Lab Invest       Date:  2006-10-30       Impact factor: 5.662

8.  CXCR4 expression is elevated in glioblastoma multiforme and correlates with an increase in intensity and extent of peritumoral T2-weighted magnetic resonance imaging signal abnormalities.

Authors:  Charles B Stevenson; Moneeb Ehtesham; Kathryn M McMillan; J Gerardo Valadez; Michael L Edgeworth; Ronald R Price; Ty W Abel; Khubaib Y Mapara; Reid C Thompson
Journal:  Neurosurgery       Date:  2008-09       Impact factor: 4.654

9.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Authors:  Bruno Nervi; Pablo Ramirez; Michael P Rettig; Geoffrey L Uy; Matthew S Holt; Julie K Ritchey; Julie L Prior; David Piwnica-Worms; Gary Bridger; Timothy J Ley; John F DiPersio
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

10.  Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth.

Authors:  Stacy Porvasnik; Noboru Sakamoto; Sergei Kusmartsev; Evgeniy Eruslanov; Wan-Ju Kim; Wengang Cao; Cydney Urbanek; Donald Wong; Steve Goodison; Charles J Rosser
Journal:  Prostate       Date:  2009-09-15       Impact factor: 4.104

View more
  17 in total

1.  Radiation-induced Notch signaling in breast cancer stem cells.

Authors:  Chann Lagadec; Erina Vlashi; Yazeed Alhiyari; Tiffany M Phillips; Milana Bochkur Dratver; Frank Pajonk
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-08-27       Impact factor: 7.038

Review 2.  G protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenues.

Authors:  A E Cherry; N Stella
Journal:  Neuroscience       Date:  2014-08-24       Impact factor: 3.590

Review 3.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

4.  Multifaceted C-X-C Chemokine Receptor 4 (CXCR4) Inhibition Interferes with Anti-Vascular Endothelial Growth Factor Therapy-Induced Glioma Dissemination.

Authors:  Jean-Pierre Gagner; Yasmeen Sarfraz; Valerio Ortenzi; Fawaz M Alotaibi; Luis A Chiriboga; Awab T Tayyib; Garry J Douglas; Eric Chevalier; Barbara Romagnoli; Gérald Tuffin; Michel Schmitt; Guillaume Lemercier; Klaus Dembowsky; David Zagzag
Journal:  Am J Pathol       Date:  2017-07-20       Impact factor: 4.307

5.  In vitro formation of neuroclusters in microfluidic devices and cell migration as a function of stromal-derived growth factor 1 gradients.

Authors:  Sean McCutcheon; Uchenna Unachukwu; Ankush Thakur; Robert Majeska; Stephen Redenti; Maribel Vazquez
Journal:  Cell Adh Migr       Date:  2016-01-08       Impact factor: 3.405

6.  Kruppel-like factor-9 (KLF9) inhibits glioblastoma stemness through global transcription repression and integrin α6 inhibition.

Authors:  Mingyao Ying; Jessica Tilghman; Yingying Wei; Hugo Guerrero-Cazares; Alfredo Quinones-Hinojosa; Hongkai Ji; John Laterra
Journal:  J Biol Chem       Date:  2014-10-06       Impact factor: 5.157

7.  Mimicking brain tumor-vasculature microanatomical architecture via co-culture of brain tumor and endothelial cells in 3D hydrogels.

Authors:  Christine Wang; Jianfeng Li; Sauradeep Sinha; Addie Peterson; Gerald A Grant; Fan Yang
Journal:  Biomaterials       Date:  2019-02-27       Impact factor: 12.479

Review 8.  Emerging targets in cancer management: role of the CXCL12/CXCR4 axis.

Authors:  Monica Cojoc; Claudia Peitzsch; Franziska Trautmann; Leo Polishchuk; Gennady D Telegeev; Anna Dubrovska
Journal:  Onco Targets Ther       Date:  2013-09-30       Impact factor: 4.147

9.  Discovery and computer aided potency optimization of a novel class of small molecule CXCR4 antagonists.

Authors:  Victoria Vinader; Djevdet S Ahmet; Mohaned S Ahmed; Laurence H Patterson; Kamyar Afarinkia
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

10.  Compound K attenuates stromal cell-derived growth factor 1 (SDF-1)-induced migration of C6 glioma cells.

Authors:  Hyuck Kim; Hyo Sun Roh; Jai Eun Kim; Sun Dong Park; Won Hwan Park; Jin-Young Moon
Journal:  Nutr Res Pract       Date:  2016-03-02       Impact factor: 1.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.